JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
This disclosure relates to JAK1 pathway inhibitors and the use thereof in treating chronic lung allograft dysfunction such as, e.g., bronchiolitis obliterans syndrome.
1. A method of treating chronic lung allograft dysfunction in a subject, said method comprising administering to the subject a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the chronic lung allograft dysfunction is bronchiolitis obliterans syndrome.
3. The method of claim 1 , wherein the subject is a lung transplant recipient.
4. The method of claim 1 , wherein the subject is a double lung transplant recipient.
5. The method of claim 2 , wherein the subject suffers from Grade 0p, Grade 1, Grade 2, or Grade 3 bronchiolitis obliterans syndrome as determined by International Society for Heart and Lung Transplantation (ISHLT) criteria.
6. The method of claim 2 , wherein the treating of bronchiolitis obliterans syndrome comprises about a 10% or greater increase in FEV 1 at twelve weeks following the first administration of the selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof.
7. The method of claim 1 , wherein the selective JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is selective for JAK1 over JAK2, JAK3, and Tyk2.
8. The method of claim 1 , wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3 [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3 [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.
10. A method of reducing the risk of bronchiolitis obliterans syndrome in a subject, said method comprising administering to the subject a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the subject is a lung transplant recipient.
12. The method of claim 10 , wherein the subject is a double lung transplant recipient.
13. The method of claim 10 , wherein the selective JAK1 pathway inhibitor is selective for JAK1 over JAK2, JAK3, and Tyk2.
14. The method of claim 10 , wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3 [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.
15. The method of claim 10 , wherein the selective JAK1 pathway inhibitor is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3 [4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.
16. A method of reducing the risk of lung re-transplantation in a subject, said method comprising administering to the subject a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof.
17. A method of reducing the risk of hospitalization in a subject, said method comprising administering to said subject an effective amount of a selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, wherein said subject is (a) diagnosed with bronchiolitis obliterans syndrome; (b) has had a lung transplantation within 1 to 5 years prior to administering the selective JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, and (c) does not have a decrease in FEV 1 attributable to a cause other than bronchiolitis obliterans syndrome.
18. A method of treating bronchiolitis obliterans syndrome in a subject, said method comprising administering to the subject {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, or a pharmaceutically acceptable salt thereof.
19. The method of claim 18 , wherein the pharmaceutically acceptable salt is {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile adipic acid salt.